Fortis Healthcare Limited has informed the Exchange regarding a press release dated May 20, 2025,
FORTIS · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Fortis Healthcare reported Q4 FY25 consolidated revenues of INR 2,007 Cr, up 12.4% YoY, with operating EBITDA margin expanding to 21.7% from 21.3% in Q4 FY24. For the full year FY25, consolidated revenues grew 12.9% to INR 7,783 Cr, while operating EBITDA surged 25.3% to INR 1,588 Cr with margin improving meaningfully from 18.4% to 20.4%. The hospital business posted 14.8% revenue growth at INR 6,528 Cr with margins expanding to 20.5% (from 18.6%), driven by 9% ARPOB growth and higher occupancy at 69%. The diagnostics business (Agilus) margins excluding one-offs improved to 22.0% from 19.6%. Key strategic moves include acquisition of perpetual 'Fortis' brand rights for INR 200 Cr, definitive agreements to acquire Shrimann Superspecialty Hospital in Jalandhar (270+ beds with expansion potential), and consolidation of Agilus stake to 89.2%. The board has recommended a dividend of INR 1 per share.
Strong double-digit revenue growth and 200 bps margin expansion in the hospital business signal pricing power and operational leverage, likely to be viewed positively. However, net debt rose sharply to INR 1,694 Cr (Net Debt/EBITDA at 0.93x vs 0.17x prior year) due to the Agilus stake buyout, which warrants monitoring. The Fortis brand acquisition, Jalandhar expansion, and ~2,000 bed addition plan through FY29 provide a clear inorganic and organic growth runway for shareholders.